Table test | UK HealthCare

Events

Time	Topic	Speaker
8:30-8:45	Welcome	B. Mark Evers, MD Director, Markey Cancer Center University of Kentucky
General Session I: Assessment and Treatment of Solid Tumors
8:45-9:30	Keynote 1: Role of ETCTN in fostering cancer research in Appalachian Kentucky: Challenges and opportunities.	Charles Kunos, MD, PhD Physician Investigational Drug Branch, National Cancer Institute Washington, DC Discuss ETCTN sponsored clinical trial opportunities for Appalachian communities
9:30-10:15	Precision Treatment of Neuroendocrine Tumors	Aman Chauhan, MD Assistant Professor of Medicine University of Kentucky Erica L. Takimoto, DO Gynecologic oncologist Norton Cancer Institute Louisville, Kentucky List new treatment options for neuroendocrine tumors Provide patient specific recommendations for managing neuroendocrine tumors
10:15-10:30	Assessment And Treatment Of Solid Tumors Overview And Discussion	Session I Speakers Moderated by: Discuss the various treatments of solid tumors and how it impacts patient care
10:30-11:00	Break
11:00-11:45	Workshop 1 (Participants pick one)	Novel Surgical Strategies in GI Malignancies Michael Cavnar, MD Assistant Professor of Surgery University of Kentucky Joseph Kim, MD Chief of Surgical Oncology University of Kentucky Describe the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of GI cancers Discuss the role intraarterial chemotherapy to target metastatic liver lesions Implementing a Germline Precision Medicine Program Brook Phillips, MD Medical Oncologist St. Elizabeth Healthcare Edgewood, KY Dan Flora, MD Medical Oncologist St. Elizabeth Healthcare Edgewood, KY Describe the role of CYP2D6 genotyping in the use of tamoxifen Discuss implementation strategies for common drug metabolizing agents and their use in oncology New Therapies for AML, Targeting FLT3 and IDH Mutations Reshma Ramlal, MD Assistant Professor of Medicine University of Kentucky Describe the place in therapy of hypomethylating agents, sorafenib, ivosidenib, and enasidenib Recognize and manage adverse effects associated with these agents Hot Topics: Gene Expression Prognostic Assays in Breast Cancer and Markers of Intratumoral Heterogeneity Rachel Stewart, DO, PhD Assistant Professor of Pathology and Laboratory Medicine University of Kentucky Therese Bocklage, MD Professor of Pathology and Laboratory Medicine University of Kentucky Discuss recent results from TailorRx trial Describe gene expression assays to assess prognosis in breast cancer Identify methods to assess intratumoral heterogeneity and its impact of clinical diagnostics
11:45-1:15	Lunch with Ongoing Clinical Trials Poster Session
1:15-2:00	Workshop 2 (Participants pick one)	Implementing a CAR T-Cell Therapeutic Program Gerhardt Hildebrandt, MD, FACP Professor of Medicine, Division Chief, Hematology and Blood Marrow Transplantation University of Kentucky Amber Lawson, PharmD Assistant Professor, College of Pharmacy University of Kentucky Jennifer Christian Division of Hematology and Blood Marrow Transplantation Administrative Coordinator UK HealthCare Describe challenges and strategies to overcome them when implementing a CAR T-cell program Managing Combination Immunotherapies John Villano, MD, PhD Professor of Medicine University of Kentucky Rachael Morgan, PharmD Hematology/Oncology Clinical Pharmacist UK HealthCare Describe common indications and adverse effects associated with combination immunotherapies and their management Panel: Inherited Cancer Syndromes Rachel C. Miller, MD Associate Professor of Obstetrics and Gynecology University of Kentucky Peng Wang, MD, Assistant Professor of Medicine University of Kentucky Justine Cooper Pickarski, MS Genetic Counselor Supervisor University of Kentucky Discuss recent updates for germline testing recommendations for ovarian, prostate and pancreas cancer Identify appropriate candidates for germline testing Describe mechanisms for genetic counselor referrals Novel Advances in Next Generation Sequencing Shulin Zhang, MD, PhD Professor of Pathology and Medicine University of Kentucky a) Describe the recent advances in next generation sequencing technology Role of NGS testing in Precision Management of Hematological Malignancies Ranjana Arora, MD, MPH. FCAP Assistant Professor of Pathology and Laboratory Medicine Medical Director, Molecular Hematology Services University of Kentucky Discuss recent technology advances integral to precision medicine Explain and interpret NGS of hematological malignancies
2:00-2:30	Break
General Session II: Treatment Advances in Hematological Malignancies
2:30-3:00	Treatment Advances in CAR T-cells	Hayder Saeed, MD Assistant Professor of Medicine University of Kentucky Jacob Hodskins, MD, MS Oncologist Owensboro Health Medical Group Owensboro, Kentucky Explain a difficult relapsed case of diffuse large B cell lymphoma Describe recent clinical advances in CAR T-cell therapy
3:00-3:45	Keynote 2: The Future is Finally Here: Targeted Therapy in the Treatment of Acute Myeloid Leukemia	Eytan M. Stein, MD Hematologic Oncologist Memorial Sloan Kettering Cancer Center New York, NY Discuss place in therapy for targeted therapies for AML
3:45-4:00	Treatment Advances in Hematological Malignancies Overview and Discussion	Session II Speakers Moderated by: Firas Badin, MD Physician BHMG Hematology and Oncology Lexington, Kentucky Review the advance treatment of hematological malignancies, the benefits and its impact on patients and their care
4:00-4:30	Wrap-up